Upper extremity deep vein thrombosis - Not the same disease at a different site

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 8, 2008, Pages 1267-1268

  Watson, Henry G ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; COUMARIN; D DIMER; HEPARIN; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN; THROMBIN;

AGE DISTRIBUTION; ARM DISEASE; BLOOD CLOT LYSIS; CENTRAL VENOUS CATHETERIZATION; DECOMPRESSION SURGERY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FAMILIAL DISEASE; GENE MUTATION; HUMAN; INCIDENCE; LEG THROMBOSIS; LONG TERM CARE; LUNG EMBOLISM; NOTE; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; THORAX OUTLET SYNDROME; THROMBOPHILIA;

ARM; BLOOD COAGULATION DISORDERS; FEMALE; HUMANS; MALE; RECURRENCE; RISK FACTORS; THORACIC OUTLET SYNDROME; VENOUS THROMBOSIS;

EID: 47649099039     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03061.x     Document Type: Note

References (14)

1. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332: 1661-5.
2. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001; 345: 165-9.
3. Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HG, Williamson IJ. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: Randomised trial. BMJ 2007; 334: 674.
4. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-6.
5. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006; 355: 1780-9.
6. Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori A, Bagatella P, Frulla M, Mosena L, Tormene D, Piccioli A, Simioni P, Girolami A. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955-60.
7. Flinterman LE, van der Meer FJM, Rosendaal FR, Doggen CJM. Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost 2008; 6: 1262-6.
8. Lechner D, Wiener C, Weltermann A, Eischer L, Eichinger S, Kyrle PA. Comparison between idiopathic deep vein thrombosis of the upper and lower extremity regarding risk factors and recurrence. J Thromb Haemost 2008; 6: 1269-74.
9. Vaya A, Mira Y, Mateo J, Falco C, Villa P, Estelles A, Corella D, Fontcuberta J, Aznar J. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost 2003; 89: 452-7.
10. Martinelli I, Battaglioli T, Bucciarelli P, Passamonti SM, Mannucci PM. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 2004; 110: 566-70.
11. Joffe HV, Kucher N, Tapson VF, Goldhaber SZ. Upper-extremity deep vein thrombosis: A prospective registry of 592 patients. Circulation 2004; 110: 1605-11.
12. Spencer FA, Emery C, Lessard D, Goldberg RJ. Upper extremity deep vein thrombosis: A community-based perspective. Am J Med 2007; 120: 678-84.
13. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
14. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998; 104: 332-8.